Logo image of VERA

VERA THERAPEUTICS INC (VERA) Stock Overview

USA - NASDAQ:VERA - US92337R1014 - Common Stock

29.22 USD
+1.02 (+3.62%)
Last: 10/24/2025, 8:00:53 PM
29.22 USD
0 (0%)
After Hours: 10/24/2025, 8:00:53 PM

VERA Key Statistics, Chart & Performance

Key Statistics
Market Cap1.86B
Revenue(TTM)N/A
Net Income(TTM)-218282000
Shares63.82M
Float63.15M
52 Week High51.61
52 Week Low18.53
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-3.58
PEN/A
Fwd PEN/A
Earnings (Next)11-05 2025-11-05/bmo
IPO2021-05-14
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


VERA short term performance overview.The bars show the price performance of VERA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

VERA long term performance overview.The bars show the price performance of VERA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 100 150

The current stock price of VERA is 29.22 USD. In the past month the price increased by 3.62%. In the past year, price decreased by -28.89%.

VERA THERAPEUTICS INC / VERA Daily stock chart

VERA Latest News, Press Relases and Analysis

VERA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.53 402.76B
AMGN AMGEN INC 13.38 157.07B
GILD GILEAD SCIENCES INC 15.63 150.06B
VRTX VERTEX PHARMACEUTICALS INC 24.88 108.04B
REGN REGENERON PHARMACEUTICALS 12.66 61.26B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.75B
ARGX ARGENX SE - ADR 88.74 50.32B
ONC BEONE MEDICINES LTD-ADR 5.02 34.14B
INSM INSMED INC N/A 33.75B
NTRA NATERA INC N/A 26.42B
BNTX BIONTECH SE-ADR N/A 25.40B
BIIB BIOGEN INC 9.36 21.98B

About VERA

Company Profile

VERA logo image Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company is headquartered in Brisbane California, California and currently employs 192 full-time employees. The company went IPO on 2021-05-14. The firm is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. The company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. The company retains all global developmental and commercial rights to atacicept and MAU868.

Company Info

VERA THERAPEUTICS INC

2000 Sierra Point Parkway, Suite 1200

Brisbane California CALIFORNIA 14623 US

CEO: Marshall Fordyce

Employees: 192

VERA Company Website

VERA Investor Relations

Phone: 16507700077

VERA THERAPEUTICS INC / VERA FAQ

What does VERA THERAPEUTICS INC do?

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company is headquartered in Brisbane California, California and currently employs 192 full-time employees. The company went IPO on 2021-05-14. The firm is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. The company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. The company retains all global developmental and commercial rights to atacicept and MAU868.


What is the current price of VERA stock?

The current stock price of VERA is 29.22 USD. The price increased by 3.62% in the last trading session.


Does VERA THERAPEUTICS INC pay dividends?

VERA does not pay a dividend.


How is the ChartMill rating for VERA THERAPEUTICS INC?

VERA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What sector and industry does VERA THERAPEUTICS INC belong to?

VERA THERAPEUTICS INC (VERA) operates in the Health Care sector and the Biotechnology industry.


Is VERA THERAPEUTICS INC (VERA) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VERA.


What is the ownership structure of VERA THERAPEUTICS INC (VERA)?

You can find the ownership structure of VERA THERAPEUTICS INC (VERA) on the Ownership tab.


VERA Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to VERA. When comparing the yearly performance of all stocks, VERA turns out to be only a medium performer in the overall market: it outperformed 46.8% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

VERA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to VERA. While VERA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VERA Financial Highlights

Over the last trailing twelve months VERA reported a non-GAAP Earnings per Share(EPS) of -3.58. The EPS decreased by -60.54% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -37.73%
ROE -46.61%
Debt/Equity 0.16
Chartmill High Growth Momentum
EPS Q2Q%-93.55%
Sales Q2Q%N/A
EPS 1Y (TTM)-60.54%
Revenue 1Y (TTM)N/A

VERA Forecast & Estimates

19 analysts have analysed VERA and the average price target is 66.02 USD. This implies a price increase of 125.95% is expected in the next year compared to the current price of 29.22.


Analysts
Analysts82.11
Price Target66.02 (125.94%)
EPS Next Y-51.61%
Revenue Next YearN/A

VERA Ownership

Ownership
Inst Owners109.87%
Ins Owners1.05%
Short Float %15.74%
Short Ratio6.48